Résumé
In recent years, the advent of new tumor-targeting vectors such as monoclonal or bispecific antibodies has resulted in the development of a new generation of therapeutic radiopharmaceuticals and an increasing research interest in this field. However, the emphasis in the overwhelming majority of such studies has been on efficacy in clinical conditions or in animal models of human cancers, and little consideration has been given to the effects of the combination of these antibodies and radiation therapy.